Cataplexy--clinical aspects, pathophysiology and management strategy

Area of Science:

• Neurology
• Sleep Medicine

Background:

• Cataplexy is the defining symptom of narcolepsy, characterized by sudden, temporary muscle paralysis during wakefulness.
• It is often underdiagnosed due to variable presentation and triggers, primarily strong positive emotions like laughter.
• The condition is strongly associated with the depletion of hypothalamic orexin neurons.

Approach:

• This review synthesizes current knowledge on the clinical and pathophysiological aspects of cataplexy.
• It explores the proposed mechanisms involving brainstem circuitry and neurotransmitter imbalances (noradrenergic, GABAergic, glycinergic).
• Neural pathways involving the amygdala and medial prefrontal cortex are implicated in emotion-induced cataplexy.

Key Points:

• Cataplexy results from the inappropriate activation of REM sleep muscle atonia pathways during wakefulness.
• Muscle weakness is mediated by reduced noradrenergic excitation and increased GABAergic/glycinergic inhibition of motor neurons.
• Emotional triggers likely involve amygdala and medial prefrontal cortex pathways.

Conclusions:

• Despite advances in understanding cataplexy's pathophysiology, current treatments remain largely symptomatic.
• Antidepressants and gamma-hydroxybutyrate are the most effective pharmacological interventions.
• Optimal therapeutic strategies require a comprehensive approach to managing this narcolepsy symptom.